Effects of N-3 fatty acids on hepatic triglyceride content in humans

被引:45
作者
Vega, Gloria Lena [1 ,2 ,3 ,5 ]
Chandalia, Manisha [1 ,4 ]
Szczepaniak, Lidia S. [4 ]
Grundy, Scott M. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Ctr Human Nutr, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Donald W Reynolds Cardiovasc Res Ctr, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Clin Nutr, Dallas, TX 75390 USA
[4] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[5] Vet Affairs Med Ctr, Metab Unit, Dallas, TX USA
关键词
ectopic liver fat; N-3 fatty acids;
D O I
10.2310/JIM.0b013e318177024d
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Because dietary N-3 fatty acids reduce plasma triglycerides, they may also decrease hepatic triglyceride content. If so, N-3 fatty acids might constitute a therapy for fatty liver. Methods: Twenty-two subjects were recruited into a study designed to test the effects of N-3 fatty acids on liver fat content. Seventeen completed the trial that had a sequential design of 4-week placebo followed by an 8-week treatment with 9 g/d of fish oil. Liver fat was measured during placebo and treatment by magnetic resonance spectroscopy. Compliance was assessed by capsule count at the end of each study phase and measurement of fatty acid composition in plasma triglyceride and phospholipid. Plasma lipoproteins and adiponectin were also measured. Results: Treatment with fish oils reduced significantly levels of plasma triglyceride by 46% (P <.03), very low-density lipoprotein + intermediate density lipoprotein cholesterol by 21% (P <.03), total apolipoprotein B by 15% (P <.03). In contrast to the changes in plasma triglycerides, hepatic triglyceride content was not significantly reduced by fish oil treatment. Conclusions: N-3 fatty acids at high doses lower plasma triglyceride levels, but there are no significant decreases in hepatic content of triglyceride for the group as a whole. Whereas the triglyceride lowering is uniform, the liver response is more variable.
引用
收藏
页码:780 / 785
页数:6
相关论文
共 38 条
[1]   Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes [J].
Bajaj, M ;
Suraamornkul, S ;
Pratipanawatr, T ;
Hardies, LJ ;
Pratipanawatr, W ;
Glass, L ;
Cersosimo, E ;
Miyazaki, Y ;
DeFronzo, RA .
DIABETES, 2003, 52 (06) :1364-1370
[2]   Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis [J].
Balas, Bogdan ;
Belfort, Renata ;
Harrison, Stephen A. ;
Darland, Celia ;
Finch, Joan ;
Schenker, Steven ;
Gastaldelli, Amalia ;
Cusi, Kenneth .
JOURNAL OF HEPATOLOGY, 2007, 47 (04) :565-570
[3]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[4]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[5]   Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study [J].
Capanni, M ;
Calella, F ;
Biagini, MR ;
Genise, S ;
Raimondi, L ;
Bedogni, G ;
Svegliati-Baroni, G ;
Sofi, F ;
Milani, S ;
Abbate, R ;
Surrenti, C ;
Casini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) :1143-1151
[6]   Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity [J].
Chan, DC ;
Watts, GF ;
Mori, TA ;
Barrett, PHR ;
Redgrave, TG ;
Beilin, LJ .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2003, 77 (02) :300-307
[7]   CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans [J].
Chandler, CE ;
Wilder, DE ;
Pettini, JL ;
Savoy, YE ;
Petras, SF ;
Chang, G ;
Vincent, J ;
Harwood, HJ .
JOURNAL OF LIPID RESEARCH, 2003, 44 (10) :1887-1901
[8]   Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids [J].
Davidson, Michael H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (4A) :27I-33I
[9]  
DELUIS DA, 2007, DIABETES RES CLIN PR
[10]  
FOLCH J, 1957, J BIOL CHEM, V226, P497